Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac trial)

• Published in: BMC medical research methodology Vol. 18; no. 1; p. 125
• Main Authors: Murray, Macey L, Meadows, Jade, Doré, Caroline J, Copas, Andrew J, Haddow, Lewis J, Lacey, Charles, Jit, Mark, Soldan, Kate, Bennett, Kate, Tetlow, Michelle, Nathan, Mayura, Gilson, Richard
• Format: Journal Article
• Language: English
• Published: England BioMed Central 06.11.2018; BMC
• Subjects: Anogenital warts; Antiviral drugs; Cryotherapy; Disease prevention; Evidence-based medicine; Health services; Hepatitis; HIV; Human immunodeficiency virus; Human papillomavirus; Imiquimod; Infections; Podophyllotoxin; Quadrivalent HPV vaccine; Study Protocol; Systematic review; Vaccines; United Kingdom > UK; England; Human papillomavirus; Anogenital warts; Podophyllotoxin; Imiquimod; Quadrivalent HPV vaccine

Anogenital warts are the second most common sexually transmitted infection diagnosed in sexual health services in England. About 90% of genital warts are caused by human papillomavirus (HPV) types 6 or 11, and half of episodes diagnosed are recurrences. The best and most cost-effective treatment for...